ARS | Publication request: Evaluation of a LaSota strain-based recombinant Newcastle disease virus (NDV) expressing the glycoprotein (G) of avian metapneumovirus (aMPV) subgroup A or B as a bivalent vaccine in turkeys

Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: February 1, 2012
Publication Date: August 6, 2012
Citation: Yu, Q., Roth, J.P., Hu, H., Estevez, C., Zsak, L. 2012. Evaluation of a LaSota strain-based recombinant Newcastle disease virus (NDV) expressing the glycoprotein (G) of avian metapneumovirus (aMPV) subgroup A or B as a bivalent vaccine in turkeys [abstract]. Meeting Abstract. CDROM.

Technical Abstract: To develop a bivalent vaccine candidate, a LaSota strain-based recombinant Newcastle disease virus (NDV) clone expressing the glycoprotein (G) of avian metapneumovirus (aMPV) subgroup A or B was generated using reverse genetics. Vaccination of turkeys with the NDV/aMPV-A G or NDV/aMPV-B G recombinant virus conferred complete protection against virulent NDV challenge and partial protection against homologous aMPV-A or aMPV-B challenge. These results suggest that expression of the G protein alone is not sufficient to provide full protection against an aMPV infection. Expression of additional immunogenic aMPV proteins may be needed to induce stronger protective immunity against the aMPV infections.